Compound ID | 1051
Class: Ansamycin
| Spectrum of activity: | Gram-positive & Gram-negative |
| Details of activity: | Broad spectrum of resistance against gram +ve and -ve bacteria |
| Institute where first reported: | Pfizer Inc |
| Year first mentioned: | 1976 |
| Highest developmental phase: | Preclinical |
| Development status: | Inactive |
| External links: | |
| Citations: |
|